Los Angeles CRS for the MACS/WIHS Combined Cohort Study

摘要 加州大学洛杉矶分校多中心艾滋病队列研究(MACS)/妇女机构间研究的临床研究站点(CRS) HIV研究(WIHS)联合队列研究(CCS)建议继续记录临床、免疫学、 HIV感染者和未感染者的生理、行为、病毒学、遗传和心理社会变化 -- 与男性发生性关系(MSM)。这包括拟议的研究，以记录招募的男男性接触者的这些变化 - 以前，以及计划招募新的未经治疗和最近治疗的感染艾滋病毒的MSM(主要是非洲人 -- 和拉美裔美国人)，以维持队列。加州大学洛杉矶分校CRS将提供领导和参与 工作组、广泛的CCS和地方研究和研究出版物，以及协作的 - 队列研究，就像35年前Mac成立以来所做的那样。加州大学洛杉矶分校CRS招募了一大批 职业生涯早期的团队，并建立了来自广泛学科的联合调查人员。这些调查人员 已经制定并正在继续制定创新的建议，以增进我们对联合 艾滋病毒感染者身上出现的病态情况，以及病理生理学， 治疗和未治疗HIV感染的免疫学、遗传学和生物行为特征。广度， 加州大学洛杉矶分校CRS调查人员的热情、经验和创新，结合经验和 长期工作人员的承诺，以及我们对艾滋病毒/艾滋病研究几个领域的领导，将继续 在今后七年的CCS成功过程中发挥不可估量的作用。

Abstract The UCLA Clinical Research Site (CRS) of the Multicenter AIDS Cohort Study (MACS) / Women's Interagency ‐ ‐ ‐‐ HIV Study (WIHS) Combined Cohort Study (CCS) proposes to continue to document clinical, immunologic, ‐‐ ‐ physiologic, behavioral, virologic, genetic and psychosocial changes in HIV infected and uninfected men who ‐‐ have sex with men (MSM). This includes proposed studies to document these changes in MSM recruited ‐ previously, as well as plans to recruit new untreated and recently treated HIV infected MSM (primarily African ‐‐ and Hispanic Americans), to maintain the cohort. The UCLA CRS will provide leadership and participation in the working groups, CCS wide and local studies and research publications, as well as collaborative multi ‐ cohort studies, as it has since the inception of the MACS 35 years ago. The UCLA CRS has recruited a large team of early career and established co investigators from a wide range of disciplines. These investigators have developed, and are continuing to develop, innovative proposals to advance our understanding of co- morbid conditions that arise in people living with treated HIV infection, as well as the pathophysiology, immunology, genetics a‐nd bio-behavioral characteristics of treated and untreated HIV infection. The breadth, enthusiasm, experience and innovation of the UCLA CRS investigators, combined with the experience and commitment of the long term staff, and our leadership of several areas of HIV/AIDs research, will continue to play an invaluable role in the success of the CCS over the next seven years.